
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Piflufolastat
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Piflufolastat F 18 PET/CT in Patients with Suspected, or at High Risk for Metastatic ccRCC
Details : Piflufolastat is a Radiolabelled Compounds drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
July 25, 2025
Lead Product(s) : Piflufolastat
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 64-Cu LNTH-1363S
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Details : 64-Cu LNTH-1363S is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Sarcoma.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
March 07, 2024
Lead Product(s) : 64-Cu LNTH-1363S
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
Details : 18-F Piflufolastat is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
October 10, 2023

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 177-Lu PNT2002
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 177-Lu PNT2002 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
September 13, 2023
Lead Product(s) : 177-Lu PNT2002
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable

PSMA PET Scan and mpMRI for Prostate Cancer Detection
Details : 18-F DCFPyL is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
April 20, 2023

Details : 18-F Piflufolastat is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
May 27, 2022

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Perflutren
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Recipient : UNC Lineberger Comprehensive Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Perflutren is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of von Hippel-Lindau Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 09, 2019
Lead Product(s) : Perflutren
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Recipient : UNC Lineberger Comprehensive Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Perflutren
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
Details : Definity (Perflutren Lipid Microsphere) is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Diseases.
Product Name : Definity
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 25, 2018
Lead Product(s) : Perflutren
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Perflutren
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
Details : Definity is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 27, 2018
Lead Product(s) : Perflutren
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Perflutren
Therapeutic Area : Nephrology
Study Phase : Phase II
Recipient : University of North Carolina
Deal Size : Inapplicable
Deal Type : Inapplicable
Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension
Details : Perflutren is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 22, 2017
Lead Product(s) : Perflutren
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Recipient : University of North Carolina
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All